00241 Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

0 Analyst Rating

Wall Street analysts forecast 00241 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00241 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 5.320

Low

Averages

High

Current: 5.320

Low

Averages

High

CLSA

Outperform

maintain

2025-12-08

Reason

CLSA

Price Target

2025-12-08

maintain

Outperform

Reason

The analyst rating from CLSA for JD Health and Alibaba Health is maintained at "Outperform" due to a positive outlook for next year's growth in pharmaceutical sales and margin expansion. Despite projecting conservative guidance for 4Q25 based on a trade-in base effect, CLSA forecasts double-digit revenue growth for both companies next year, with JD Health expected to grow at a faster pace. The target price for JD Health is set at HK$71, while Alibaba Health's target price is trimmed to HK$6 to reflect a slower growth outlook.

JPMorgan

Neutral

maintain

$6.5

2025-12-03

Reason

JPMorgan

Price Target

$6.5

2025-12-03

maintain

Neutral

Reason

The analyst rating for ALI HEALTH (00241.HK) is maintained at Neutral by JPMorgan due to a combination of factors. The company achieved strong revenue growth of 17% in 1HFY2026, primarily driven by the growth of originator drugs and structural changes in China's pharmaceutical market. However, there is uncertainty regarding the sustainability and incremental contribution of Taobao's instant retail, which could affect future sales growth. As a result, while the current momentum is positive, the broker advises caution and highlights the need to monitor fluctuations in instant retail subsidies and potential user churn. The target price is set at $6.5 based on a projected 2.5x EV/revenue multiple for FY2026.

Goldman Sachs

Neutral

maintain

2025-12-02

Reason

Goldman Sachs

Price Target

2025-12-02

maintain

Neutral

Reason

Goldman Sachs maintained a Neutral rating on ALI HEALTH (00241.HK) due to several key factors. The company is benefiting from structural industry tailwinds, such as the shift of original drugs from in-hospital channels and the growth of online drug sales. However, there is a noted divergence in revenue growth between ALI HEALTH and its competitor JD HEALTH, with ALI HEALTH lagging in establishing a comprehensive first-party (1P) business model, particularly in user awareness and supply chain capabilities. Despite this, Goldman Sachs sees potential upside in ALI HEALTH's results guidance for FY2026, driven by strong growth in its 1P platform sales and effective cost control. The target price was raised from $4.7 to $5.2, reflecting a 2027 PE ratio of 28x for its pharmacy and healthcare services projections.

UBS

downgrade

2025-12-02

Reason

UBS

Price Target

2025-12-02

downgrade

Reason

The analyst rating from UBS was downgraded due to a belief that the performance of ALI HEALTH was primarily driven by a structural shift from offline to online pharmaceutical supply, rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. Despite the company's first-party platform sales growth surpassing forecasts, UBS maintains a cautious outlook, suggesting that leading peers may benefit more from this structural trend. Consequently, while the target price was raised, the Sell rating remained in place.

CICC

upgrade

2025-11-28

Reason

CICC

Price Target

2025-11-28

upgrade

Reason

The analyst rating for ALI HEALTH (00241.HK) is maintained at "Outperform" due to several key reasons: 1. Strong Financial Performance: The company's 1HFY26 results exceeded expectations, with a revenue increase of 17% year-over-year and a non-GAAP net profit growth of 38.7%. This indicates robust operational performance, particularly in the original prescription drug category. 2. Positive Forecast Adjustments: CICC raised its non-GAAP net profit forecasts for FY2026 and FY2027 by 16%, reflecting confidence in the company's ongoing profitability and growth potential. 3. Strategic Partnerships: The anticipated strengthening of strategic partnerships with upstream enterprises is expected to enhance contributions from areas beyond product sales, indicating a diversified growth strategy. 4. Sector Valuation Uplift: The recent increase in sector valuations has led to a 30% increase in the target price to $7.1, further supporting the positive outlook on the stock. These factors collectively contribute to the analyst's favorable rating and outlook for ALI HEALTH.

CLSA

Outperform

maintain

$6.5

2025-11-28

Reason

CLSA

Price Target

$6.5

2025-11-28

maintain

Outperform

Reason

The analyst rating for ALI HEALTH was set to "Outperform" with a target price of HKD 6.5 due to several factors highlighted in the report. The company's 1HFY26 results slightly exceeded expectations, with both revenue and profit showing advancement driven by strong first-party sales, despite a miss in third-party platform performance. The adjusted net profit increased by 39% year-over-year, and the gross margin of 8.1% surpassed the broker's estimate of 7.7%. Additionally, ALI HEALTH maintained its FY2026 guidance, projecting revenue growth of 10-15% and profit growth of 20-30%, indicating confidence in future performance. The broker also anticipates sustained strong growth in sales of originator drugs, although there may be uncertainties in healthcare device sales as the effects of a trade-in program diminish.

Valuation Metrics

The current forward P/E ratio for ALI HEALTH (00241.HK) is 29.68, compared to its 5-year average forward P/E of 94.24. For a more detailed relative valuation and DCF analysis to assess ALI HEALTH 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

94.24

Current PE

29.68

Overvalued PE

418.27

Undervalued PE

-229.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-158.93

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

927.03

Undervalued EV/EBITDA

-1244.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.35

Current PS

0.00

Overvalued PS

6.41

Undervalued PS

0.29

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

00241 News & Events

Events Timeline

No data

News

4.5

12-12aastocks

HSI Rises by 446 Points; TENCENT and BABA-W Surge After Noon; HSBC HOLDINGS Reaches Record High

4.5

12-12aastocks

<Full-day Summary> HSI Gains 446 Points; HSTI Rises 103 Points; PING AN Surges Over 3%; PING AN, HSBC HOLDINGS, HYSAN DEV Reach New Peaks; Market Turnover Increases

4.5

12-11aastocks

HSI Closes with a 10-Point Decline; Chip Stocks Weaken; ZTE Plummets 13%

People Also Watch

Frequently Asked Questions

What is ALI HEALTH (00241) stock price today?

The current price of 00241 is 5.32 USD — it has increased 0.95 % in the last trading day.

What is ALI HEALTH (00241)'s business?

What is the price predicton of 00241 Stock?

Wall Street analysts forecast 00241 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00241 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ALI HEALTH (00241)'s revenue for the last quarter?

ALI HEALTH revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is ALI HEALTH (00241)'s earnings per share (EPS) for the last quarter?

ALI HEALTH. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for ALI HEALTH (00241)'s fundamentals?

The market is revising No Change the revenue expectations for 00241 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.

How many employees does ALI HEALTH (00241). have?

ALI HEALTH (00241) has 0 emplpoyees as of December 18 2025.

What is ALI HEALTH (00241) market cap?

Today 00241 has the market capitalization of 0.00 USD.

00241

Overview

Forecast

Valuation

Earnings

00241

Overview

Forecast

Valuation

Earnings

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

00241 News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is ALI HEALTH (00241) stock price today?

What is ALI HEALTH (00241)'s business?

What is the price predicton of 00241 Stock?

What is ALI HEALTH (00241)'s revenue for the last quarter?

What is ALI HEALTH (00241)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ALI HEALTH (00241)'s fundamentals?

How many employees does ALI HEALTH (00241). have?

What is ALI HEALTH (00241) market cap?